Atenolol and chlorthalidone in combination for hypertension

British Journal of Clinical Pharmacology
D N BatemanC T Dollery

Abstract

1 The hypotensive effect of single daily dosing with atenolol 100 mg and chlorthalidone 25 mg given alone or in combination has been assessed in a double-blind, crossover, placebo controlled trial in fifteen hypertensive patients. 2 Average lying blood pressures were: Placebo 155.4/103.9 mm Hg, atenolol 134.6/85.8 mm Hg, chlorthalidone 139.5/90.1 mm Hg, combination 127.7/82.5 mm Hg. 3 The effect of the combination therapy in reducing lying diastolic pressure compared with placebo (a fall of 21.4 mm Hg) was significantly less than the 31.9 mm Hg fall predicted from the sum of the individual effects (P = 0.01). 4 Observations on blood pressure at rest and under mental, isometric and bicycle ergometer stress were made pre-dose and post-dose for a 12 h period at the end of the last treatment period. 5 Lying blood pressure declined from the zero hour (pre-dose) reading on all treatments to a low at 15.00--18.00 h and then rose again. 6 The rise in systolic blood pressure after isometric exercise and mental stress was of a similar magnitude with all four treatment regimes. 7 Atenolol, alone and in combination with chlorthalidone, reduced the blood pressure and the pulse rate increase on exercise 2 h post-dose when compared with readi...Continue Reading

References

Jul 1, 1977·Clinical Pharmacology and Therapeutics·J HettiarachchiW S Watson
Oct 1, 1977·British Journal of Clinical Pharmacology·T A JeffersN P Barker
Nov 1, 1977·Clinical Pharmacology and Therapeutics·M G TweeddaleJ Ruedy
Apr 17, 1976·British Medical Journal·R M PearsonA M Breckenridge
Apr 24, 1976·British Medical Journal·A P Douglas-Jones, J M Cruickshank
May 1, 1976·Clinical Pharmacology and Therapeutics·M G MyersC T Dollery
Apr 6, 1968·Lancet·W Hughes
Aug 1, 1974·Journal of Chronic Diseases·C J BulpittS Carne
Jul 1, 1974·The Journal of Clinical Investigation·C E MartinJ J Leonard
Nov 9, 1963·Lancet·W I CRANSTONL M MUTCH

❮ Previous
Next ❯

Citations

Jan 1, 1985·European Journal of Clinical Pharmacology·M CatalanoA Libretti
Jan 1, 1980·Pharmacology & Therapeutics·B N Prichard, C W Owens
Jan 1, 1983·Pharmacology & Therapeutics·A J Scriven, P J Lewis
Jan 1, 1979·Current Medical Research and Opinion·R M Goodfellow
Apr 20, 2010·Journal of the American Society of Hypertension : JASH·Alan H GradmanMichael A Weber
Mar 4, 2011·The Journal of Clinical Hypertension·Alan H GradmanUNKNOWN American Society of Hypertension Writing Group
Apr 9, 2010·Journal of the American Society of Hypertension : JASH·Alan H GradmanUNKNOWN American Society of Hypertension Writing Group
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Jenny Mh ChenJames M Wright
May 30, 2014·The Cochrane Database of Systematic Reviews·Vijaya M MusiniJames M Wright
Jan 1, 1984·The Journal of International Medical Research·S Gentile, M Coltorti
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Jenny Mh ChenJames M Wright
Mar 11, 2016·The Cochrane Database of Systematic Reviews·Gavin W K WongJames M Wright
Mar 1, 1989·Journal of Clinical Pharmacology·F GallettiM Mancini
Feb 1, 1987·Clinical and Experimental Pharmacology & Physiology·G I AdebayoA F Mabadeje

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.